Evolution of the Average Target: Summit Therapeutics Inc.

Evolution of the Target Price: Summit Therapeutics Inc.

Changes in Analyst Recommendations: Summit Therapeutics Inc.

edfee1.xYZX0X3h1G7OuliKAloiOrOantvkpVCXskE0Fy8nAhA.rMMTuhaboj6kzh_dbgl6Tcfir4K06QLShSRNVUJuZEmIsA7mJ6uyXJj8GQ~c91aebd13ce839ba3ceca55b4c14be5a
25/08 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
12/08 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
25/07 Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept MT
22/06 Analyst recommendations: Accenture, Conocophillips, Diamondback Energy, Oracle, Applied Materials… Zonebourse
27/05 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
22/05 Summit Therapeutics Shares Fall After HC Wainwright Downgrade MT
22/05 Bernstein Initiates Summit Therapeutics at Underperform MT
22/05 HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy MT
04/05 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
17/12 Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16 MT
21/25/21 Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley… Zonebourse
20/25/20 Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results CI
17/25/17 Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target MT
04/25/04 Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target MT
19/25/19 Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target MT
13/25/13 Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says MT
01/25/01 UBS Initiates Summit Therapeutics at Buy With $30 Price Target MT
11/25/11 Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target MT
08/25/08 TD Cowen Initiates Summit Therapeutics at Buy MT
25/25/25 Top Midday Decliners MT
26/25/26 Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23 MT
21/25/21 Cantor Fitzgerald Initiates Summit Therapeutics at Overweight MT
12/25/12 Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target MT
28/25/28 Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target MT
08/25/08 Truist Initiates Summit Therapeutics at Buy With $35 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+108.38%
+16.85%
+9.86%
+17.86%
+68.87%
+10.81%
-13.15%
+12.58%
+20.2%
-2.66%
Average +24.96%
Weighted average by Cap. +19.78%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
10.13GBP
Average target price
21.05GBP
Spread / Average Target
+107.92%
High Price Target
30.81GBP
Spread / Highest target
+204.26%
Low Price Target
8.094GBP
Spread / Lowest Target
-20.07%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. SMMT Stock
  4. Consensus Summit Therapeutics Inc.